Jump to section
To help dogs everywhere live longer, healthier lives.
People love their dogs, with many owners willing to do almost anything to get more time with their furry companions. Loyal addresses this, by developing drugs that target dog ageing and its associated health challenges.
Leveraging cutting-edge research and advanced scientific methodologies, the company formulates pharmaceuticals that not only extend dogs' lifespans but also improve overall quality of life. By collaborating with leading experts in veterinary medicine and biotechnology, Loyal aims to bring these life-extending treatments to the market, offering hope to pet owners and their beloved companions.
The future of Loyal looks promising, as it leads the way in advancing pet longevity and health. With a strong commitment to innovation and ongoing efforts to gain FDA approval for its drugs, Loyal is all set to transform the pet healthcare industry.
Steph
Company Specialist at Welcome to the Jungle
Mar 2024
$45m
SERIES B
Apr 2022
$13m
SERIES A
This company has top investors
Celine Halioua
(CEO)Previously the Chief of Staff at The Longevity Fund. They were also a Scientific Consultant at Oisín Biotechnologies and a Researcher of Neuro-oncology at Sanford Burnham Prebys Medical Discovery Institute.